Evidence map›Paper›PMID 28331041›Full record

ArticleThe European respiratory journal2017

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.

Marieke J van der Werf, Vahur Hollo, Csaba Ködmön, Masoud Dara, Mike Catchpole

Abstract readLetter
In one paragraph

Article in The European respiratory journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2019
    Guideline
  2. Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  3. Article
  4. Observational
  5. Tuberculosis elimination: where are we now?European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Marieke J van der WerfEuropean Centre for Disease Prevention and Control, Stockholm, Sweden marieke.vanderwerf@ecdc.europa.eu.
Vahur HolloEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Csaba KödmönEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Masoud DaraWorld Health Organization Regional Office for Europe, Copenhagen, Denmark.
Mike CatchpoleEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.

Funding

World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antitubercular AgentsDrug Administration ScheduleEuropean UnionHumansMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular Agents

Identifiers

PMID28331041
PMCPMC5898943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.